Concept and synthetic approach for a kilogram scale synthesis of octa- d-arginine amide nonahydrochloride salt von Califano, J.C., Uribe, A., Chang, J.L., Becker, C.L., Napier, J.J., Kishore, V., Zhou, D., Love, G., Gernhardt, K., Tolle, J.C.

Volltext

Ultrafast Trap State-Mediated Electron Transfer for Quantum Dot Redox Sensing von Harvie, Andrew J, Smith, Charles T, Ahumada-Lazo, Ruben, Jeuken, Lars J. C, Califano, Marco, Bon, Robin S, Hardman, Samantha J. O, Binks, David J, Critchley, Kevin

Volltext

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOS... von Felip, E, Cho, B.C, Gutierrez, V, Alip, A, Besse, B, Lu, S, Spira, A.I, Girard, N, Califano, R, Gadgeel, S.M, Yang, J.C.-H, Yamamoto, S, Azuma, K, Kim, Y.J, Lee, K.-H, Danchaivijitr, P, Ferreira, C.G, Cheng, Y, Sendur, M.A.N, Chang, G.-C, Wang, C.-C, Prabhash, K, Shinno, Y, Stroyakovskiy, D, Paz-Ares, L, Rodriguez-Cid, J.R, Martin, C, Campelo, M.R.G, Hayashi, H, Nguyen, D, Tomasini, P, Gottfried, M, Dooms, C, Passaro, A, Schuler, M, Gelatti, A.C.Z, Owen, S, Perdrizet, K, Ou, S.-H.I, Curtin, J.C, Zhang, J, Gormley, M, Sun, T, Panchal, A, Ennis, M, Fennema, E, Bauml, J.M, Daksh, M, Sethi, S, Lee, S.-H

Volltext

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOS... von Felip, E., Cho, B.C., Gutiérrez, V., Alip, A., Besse, B., Lu, S., Spira, A.I., Girard, N., Califano, R., Gadgeel, S.M., Yang, J.C.-H., Yamamoto, S., Azuma, K., Kim, Y.J., Lee, K.-H., Danchaivijitr, P., Ferreira, C.G., Cheng, Y., Sendur, M.A.N., Chang, G.-C., Wang, C.-C., Prabhash, K., Shinno, Y., Stroyakovskiy, D., Paz-Ares, L., Rodriguez-Cid, J.R., Martin, C., Campelo, M.R.G., Hayashi, H., Nguyen, D., Tomasini, P., Gottfried, M., Dooms, C., Passaro, A., Schuler, M., Gelatti, A.C.Z., Owen, S., Perdrizet, K., Ou, S.-H.I., Curtin, J.C., Zhang, J., Gormley, M., Sun, T., Panchal, A., Ennis, M., Fennema, E., Daksh, M., Sethi, S., Bauml, J.M., Lee, S.-H.

Volltext

29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results von Tiseo, M., Popat, S., Kim, H.R., Ahn, M-J., Yang, J.C., Han, J-Y., Hochmair, M.J., Lee, K.H., Delmonte, A., Garcia Campelo, M.R., Kim, D-W., Griesinger, F., Felip, E., Califano, R., Spira, A.I., Gettinger, S.N., Lin, H.M., Liu, Y., Vranceanu, F., Camidge, D.R.

Volltext

1195P Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L von Popat, S., Kim, H.R., Ahn, M-J., Yang, J.C., Han, J-Y., Hochmair, M.J., Lee, K.H., Delmonte, A., Campelo, M.R. Garcia, Kim, D-W., Griesinger, F., Felip, E., Califano, R., Spira, A., Gettinger, S.N., Tiseo, M., Lin, H.M., Liu, Y., Vranceanu, F., Camidge, D.R.

Volltext

1300P Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial von Popat, S., Kim, H.R., Ahn, M-J., Yang, J.C-H., Han, J-Y., Hochmair, M.J., Lee, K.H., Delmonte, A., Campelo, M.R. Garcia, Kim, D-W., Griesinger, F., Felip, E., Califano, R., Spira, A., Gettinger, S., Tiseo, M., Ni, Q., Zhang, P., Camidge, D.R.

Volltext

1304P Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L von Ahn, M-J., Kim, H.R., Yang, J.C-H., Han, J-Y., Li, J.Y-C., Hochmair, M.J., Chang, G-C., Delmonte, A., Lee, K.H., Campelo, M.R. Garcia, Gridelli, C., Spira, A., Califano, R., Griesinger, F., Ghosh, S., Felip, E., Kim, D-W., Zhang, P., Popat, S., Camidge, D.R.

Volltext

Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial von Popat, S., Kim, H.R., Ahn, M.-J., Yang, J.C.-H., Han, J.-Y., Hochmair, M.J., Lee, K.H., Delmonte, A., Garcia Campelo, M.R., Kim, D.-W., Griesinger, F., Felip, E., Califano, R., Spira, A.I., Gettinger, S., Tiseo, M., Haney, J., Kerstein, D., Camidge, D.R.

Volltext

Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial von Camidge, R., Kim, H.R., Ahn, M.-J., Yang, J.C.-H., Han, J.-Y., Hochmair, M.J., Lee, K.H., Delmonte, A., Garcia Campelo, M.R., Kim, D.-W., Griesinger, F., Felip, E., Califano, R., Spira, A., Gettinger, S., Tiseo, M., Ni, Q., Zhang, P., Popat, S.

Volltext

PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L) von Camidge, R., Kim, H.R., Ahn, M., Yang, J.C., Han, J., Lee, J., Hochmair, M., Li, J.Y., Chang, G., Lee, K., Gridelli, C., Delmonte, A., Garcia Campelo, M.R., Kim, D., Bearz, A., Griesinger, F., Morabito, A., Felip, E., Califano, R., Ghosh, S., Spira, A., Gettinger, S., Tiseo, M., Haney, J., Kerstein, D., Popat, S.

Volltext

Reluctance to Undergo Follow-Up Screening for Head and Neck Cancer Is Associated with Income, Gender, and Tobacco Use von Shan, Shannon J.C., Zahurak, Marianna, Khan, Zubair, Califano, Joseph A.

Volltext